User login
Article Type
Changed
Fri, 01/04/2019 - 11:12
Display Headline
A line-up of new therapies and expanded combinations
Monotherapy with ibrutinib prolonged survival longer than did standard chemotherapy using chlorambucil in the front-line treatment of older patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the phase 3 RESONATE-2 study.The developers of the drug had announced last summer that ibrutinib, an orally bioavailable, small-molecule inhibitor of Bruton’s tyrosine kinase, had achieved its primary and secondary endpoints. But the first full look at the data at the meeting showed ibrutinib reduced the risk of progression or death by 84% by independent review, compared with chlorambucil, which has been a standard first-line therapy in older CLL patients.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(3)
Page Number
132-136
Legacy Keywords
multiple myeloma, ibrutinib, chronic lymphocytic leukemia, CLL, small lymphocytic lymphoma, SLL, ixazomib, idelalisib, liver toxicity, acute myeloid leukemia, AML, myelodysplastic syndrome, MDS
Sections
Article PDF
Article PDF
Monotherapy with ibrutinib prolonged survival longer than did standard chemotherapy using chlorambucil in the front-line treatment of older patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the phase 3 RESONATE-2 study.The developers of the drug had announced last summer that ibrutinib, an orally bioavailable, small-molecule inhibitor of Bruton’s tyrosine kinase, had achieved its primary and secondary endpoints. But the first full look at the data at the meeting showed ibrutinib reduced the risk of progression or death by 84% by independent review, compared with chlorambucil, which has been a standard first-line therapy in older CLL patients.
Click on the PDF icon at the top of this introduction to read the full article.
Monotherapy with ibrutinib prolonged survival longer than did standard chemotherapy using chlorambucil in the front-line treatment of older patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the phase 3 RESONATE-2 study.The developers of the drug had announced last summer that ibrutinib, an orally bioavailable, small-molecule inhibitor of Bruton’s tyrosine kinase, had achieved its primary and secondary endpoints. But the first full look at the data at the meeting showed ibrutinib reduced the risk of progression or death by 84% by independent review, compared with chlorambucil, which has been a standard first-line therapy in older CLL patients.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(3)
Issue
The Journal of Community and Supportive Oncology - 14(3)
Page Number
132-136
Page Number
132-136
Article Type
Display Headline
A line-up of new therapies and expanded combinations
Display Headline
A line-up of new therapies and expanded combinations
Legacy Keywords
multiple myeloma, ibrutinib, chronic lymphocytic leukemia, CLL, small lymphocytic lymphoma, SLL, ixazomib, idelalisib, liver toxicity, acute myeloid leukemia, AML, myelodysplastic syndrome, MDS
Legacy Keywords
multiple myeloma, ibrutinib, chronic lymphocytic leukemia, CLL, small lymphocytic lymphoma, SLL, ixazomib, idelalisib, liver toxicity, acute myeloid leukemia, AML, myelodysplastic syndrome, MDS
Sections
Citation Override
JCSO 2016;14:132-136
Disallow All Ads
Alternative CME
Article PDF Media
Document